The Cellular Ataxia Telangiectasia-Mutated Kinase Promotes Epstein-Barr Virus Lytic Reactivation in Response to Multiple Different Types of Lytic Reactivation-Inducing Stimuli

Stacy R. Hagemeier,a Elizabeth A. Barlow,a Qiao Meng,a and Shannon C. Kenneyab
McArdle Laboratory for Cancer Research, Department of Oncology,a and Department of Medicine,b University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

The Epstein-Barr virus (EBV) latent-to-lytic switch is mediated by the viral proteins BZLF1 (Z), BRLF1 (R), and BRRF1 (Na). Since we previously showed that DNA-damaging agents (including chemotherapy and irradiation) can induce EBV lytic reactivation and recently demonstrated that wild-type p53 contributes to lytic reactivation, we investigated the role of the ATM kinase during EBV reactivation. ATM phosphorylates and activates p53, as well as numerous other substrates involved in the cellular DNA damage response. Using an ATM inhibitor (KU55933), we found that ATM activity is required for efficient induction of EBV lytic gene expression by a variety of different stimuli, including a histone deacetylase (HDAC) inhibitor, the transforming growth factor β (TGF-β) cytokine, a demethylating agent (5-azacytidine), B cell receptor engagement with anti-IgG antibody, hydrogen peroxide, and the proteasome inhibitor bortezomib. In EBV-infected AGS (gastric) cells, knockdown of ATM, or p53, expression inhibits EBV reactivation. Conversely, treatment of these cells with nutlin-3 (which activates p53 and ATM) robustly induces lytic reactivation in a p53+- and ATM-dependent manner. The ability of the EBV R and Na proteins to induce lytic reactivation in EBV-infected AGS cells is ATM dependent. However, overexpression of Z induces lytic gene expression in the presence or absence of ATM activity. Our results suggest that ATM enhances Z promoter activity in the context of the intact EBV genome and that p53 contributes to the ATM effect. Nevertheless, since we found that ATM inhibitors also reduce lytic reactivation in Burkitt lymphoma cells that have no p53, additional ATM substrates must also contribute to the ATM effect.

E

stein-Barr virus (EBV) is a gammaherpesvirus that is the cause of infectious mononucleosis and is associated with a variety of epithelial and B cell cancers, including nasopharyngeal carcinoma (NPC), a subset of gastric carcinomas, Burkitt lymphoma (BL), and Hodgkin’s disease (77, 102). Like all herpesviruses, EBV can infect cells in either latent or lytic forms. Following infection of humans, EBV establishes long-term viral latency in the memory B cell compartment but can be reactivated to undergo the lytic form of infection following plasma cell differentiation (51). EBV infection of normal epithelial cells generally results in lytic infection (32, 93, 94), although EBV+ epithelial cell tumors such as NPCs and gastric carcinomas are primarily composed of cells with latent forms of infection (48, 77). Both the latent and lytic forms of EBV infection are essential for the long-term success of the virus, and the latent-lytic switch is tightly controlled by both cellular and viral factors.

The two EBV immediate-early (IE) proteins, BZLF1 (Z, also known as Zta, ZEBRA, or EB1) and BRLF1 (R), are transcription factors that activate expression of lytic viral promoters, and overexpression of either the Z or R IE protein is sufficient to reactivate the lytic form of EBV infection in many latently infected cell lines (2, 16, 18–20, 23, 27, 34, 39, 47, 48, 57, 69, 76, 80, 89, 99). In addition, expression of the BRRF1-encoded early gene product, Na, is sufficient to reactivate the lytic form of EBV infection in some latently infected epithelial cell lines, due to the ability of Na to activate the Z promoter indirectly through cellular factors (38, 42). Therefore, the cellular and viral proteins that regulate Z, R, and Na gene expression play a key role in determining if EBV infection is latent or lytic.

Cells containing the latent forms of EBV infection can be switched to the lytic form of infection by using a variety of different lytic reactivation-inducing stimuli, including histone deacetylase (HDAC) inhibitors (HDACi) (29, 58), B cell receptor (BCR) engagement with anti-IgG antibody (65, 88), transforming growth factor β (TGF-β) (25), the proteasome inhibitor bortezomib (85), the demethylating agent 5-azacytidine (4), radiation (95), and chemotherapeutic agents (28). These stimuli are thought to promote lytic EBV reactivation primarily through their ability to regulate cellular factors that control the activity of the Z and R promoters. In addition, cellular factors that regulate Z and R transcriptional function likewise contribute to the balance between latent and lytic infection; for example, we recently reported that the B cell-specific Oct-2 protein promotes viral latency by directly interacting with Z and inhibiting its transcriptional function, while the cellular Oct-1 protein promotes viral reactivation by interacting directly with R and enhancing its transcriptional function (78, 79).

At least two of the various different lytic reactivation-inducing stimuli (chemotherapy and radiation) are well-known DNA-damaging agents, although the mechanism(s) by which these two particular agents induce lytic reactivation has not been well studied. Since we recently showed that the tumor suppressor protein p53 greatly facilitates lytic reactivation induced by overexpression of the EBV Na (BRRF1) and R proteins (38), and DNA damage...
potently activates p53 transcriptional function (84, 86), DNA-damaging agents could potentially induce EBV reactivation (at least partially) via activation of p53. Recently, p53 was also shown to be required for HDACi-mediated lytic reactivation in both EBV-positive nasopharyngeal carcinoma cell lines and lymphoblastoid B cell lines (13, 17, 38), further confirming a critical role of p53 function in controlling EBV reactivation in a variety of different settings.

The ataxia telangiectasia-mutated (ATM) protein is a cellular serine/threonine kinase that plays a key role in mediating the cellular response to DNA damage (5, 41, 45). In response to DNA damage, ATM becomes activated via phosphorylation at Ser-1981 and phosphorylates multiple substrates, including p53, γH2AX, Kap1, and Chk2 (87). ATM-mediated phosphorylation of p53 on serine 15 plays a critical role in activating p53 function in response to DNA damage (101), suggesting that the ability of DNA-damaging agents to reactivate EBV might be mediated through ATM. The ATM kinase is also activated in response to reactive oxygen species (ROS) in the absence of DNA damage (36, 37). ROS activates ATM by inducing a conformational alteration in the protein that is not associated with Ser-1981 phosphorylation (37), and thus, measuring the amount of ATM phosphorylation at this site (although commonly used to monitor ATM activation in cells) does not detect ROS-mediated ATM activation.

Interestingly, ATM inhibits the ability of EBV to transform primary B cells (72), and ATM kinase expression is reduced in EBV-associated nasopharyngeal carcinomas (9). Of note, several EBV latent proteins (EBNA1, EBNA3C, and LMP1) have been shown to inhibit the DNA damage response (10, 35), and LMP1 in EBV latent proteins (EBNA1, EBNA3C, and LMP1) have been shown to inhibit the DNA damage response (101). ATM is also required for efficient EBV reactivation in cell lines that express wild-type (WT) p53, we find that ATM activity is also required for efficient EBV reactivation in cell lines that do not express wild-type p53. These results suggest that ATM plays an unexpectedly important role in promoting lytic EBV reactivation via both p53-dependent and p53-independent mechanisms.

**MATERIALS AND METHODS**

**Cell lines.** AGS-Akata/8X1 cells (wild-type p53) were a gift from Lindsey Hutt-Fletcher and are gastric carcinoma cells superinfected with the Akata strain of EBV, which contains the green fluorescent protein (GFP) open reading frame under the control of the BXLFL1 promoter (8, 63). AGS-Akata cells were maintained in F-12 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (Pen-Strep), and G418 (400 µg/ml). EBV-negative AGS gastric carcinoma cells (obtained from the American Type Culture Collection [ATCC]) were maintained in F-12 medium supplemented with 10% FBS and 1% Pen-Strep. Mutu I and Kem I cells (a gift from Alan Rickinson and Jeff Sample) are EBV-positive Burkitt lymphoma type I latency cells with mutant p53 and were maintained in RPMI 1640 supplemented with 10% FBS and 1% Pen-Strep (33, 41, 73, 81, 96). Kem III cells (a gift from Alan Rickinson and Jeff Sample) are EBV-positive Burkitt lymphoma type III cells with wild-type p53 (41, 81). Raji cells (EBV-positive Burkitt lymphoma, from the ATCC) were maintained in RPMI 1640 supplemented with 10% FBS and Pen-Strep. Akata-GFP BL cells (a gift from Kenzo Takada [received from Bill Sugden]) are derived from a type I latency Burkitt lymphoma line (Akata BL) that lost the endogenous EBV genome and then was superinfected with an Akata EBV containing inserted GFP and G418 resistance genes as previously described (46). Akata (and Akata-GFP) BLs do not express p53 (26) and were maintained in RPMI 1640 supplemented with 10% FBS, 1% Pen-Strep, and 500 µg/ml G418. EBV-infected 293 cells (a gift from H.-J. Delecluse) have been previously described (21, 27) and were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with hygromycin (100 µg/ml), 10% FBS, and Pen-Strep. EBV-negative Daudi cells (a gift from Kenzo Takada via Bill Sugden) are Burkitt lymphoma cells that lost the endogenous EBV genome and were maintained in RPMI 1640 supplemented with 10% FBS and 1% Pen-Strep (70). Lymphoblastoid cell line (LCL) donor 4 cells are early-passage lymphoblastoid B cells transformed with wild-type B95.8 EBV as previously described and were maintained in RPMI 1640 supplemented with 10% FBS and 1% Pen-Strep (42). LCL donor 4 cells are thought to have wild-type p53 based on the literature (96).

To generate AGS-WT (B95.8) and AGS-PKmut cell lines, previously described 293 cells latently infected with wild-type (WT) B95.8 or PK (BGLF4) mutant EBV (66) were transfected with Z and R and gpl10 expression plasmids to induce virus production. Three days posttransfection, virus was harvested and filtered through a 0.8-µm filter, EBV-negative Daudi cells were then incubated with the WT or PKmut virus for 1 h and then cocultured with EBV-negative AGS cells for several days. The Daudi cells were then removed, and infected AGS cells were selected with hygromycin (100 µg/ml) to establish stable cell lines.

**Plasmids.** Plasmid DNA was purified using Qiagen maxiprep columns according to the manufacturer’s protocol. pSG5 was obtained from Stratagene. pSG5-Z, containing the genomic Z sequence transcribed from a simian virus 40 (SV40) promoter, and pSG5-R, containing the genomic sequence encoding R beginning from the second exon but lacking the Na-encoding first exon, were a gift from Diane Hayward (39). pSG5-FLAGNa contains a FLAG tag on the amino terminus of the Na open reading frame (38). pRK-BALF4 codes for the EBV glycoprotein 110 and was a gift from H.-J. Delecluse (71).

**DNA transfection.** DNA was transfected into 293 cells using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s protocol. AGS-Akata cells were transfected with DNA using Fugene HD reagent (Promega) according to the manufacturer’s protocol.

**Chemical reagents.** The following chemical reagents were used to induce EBV lytic infection, and cells were treated for 48 h unless otherwise stated: phorbol 12-myristate 13-acetate (TPA; 20 ng/ml; Sigma), paclitaxel (5 µg/ml; Calbiochem), sodium butyrate (3 mM; Sigma), cis-diammineplatinum(II) dichloride (cisplatin; 10 µM; Sigma), suberoylanilide hydroxamic acid (SAAH; 5 µM; Cayman Chemical), hydrogen peroxide (H₂O₂; 300 µM; Mallinckrodt Chemical), recombinant human TGF-β (5 µg/ml; R&D Systems), anti-human IgG (10 µg/ml; Sigma), 5-aza-2’-deoxycytidine (5’-azacytidine; 1 µM; Sigma), nutlin-3 (10 µM; Calbiochem), and bortezomib (20 nM; Selleck Chemical). For ATM inhibitor
experiments, cells were pretreated for 1 h with the ATM inhibitor KU55933 (10 µM; Calbiochem).

**Virus titration assay.** Virus titration assays were performed as previously described (42). EBV-infected 293 cells were transfected with BZLF1 and BALKF4 (gp110) expression vectors and treated with or without the ATM inhibitor KU55933. Experiments with each condition were performed in triplicate. Supernatant was harvested 72 h posttransfection and filtered through a 0.8-µm-pore-size filter. Raji cells (2 × 10^7 cells/infec- tion) were infected with various amounts of virus and incubated at 37°C. Phorbol 12-myristate 13-acetate (TPA; 20 ng/ml) and sodium butyrate (3 mM final concentration) were added 24 h after infection. GFP-positive Raji cells were counted by flow cytometry to determine viral titer.

**Western blot analysis.** Western blot analysis was performed as previously described (1, 6). Cell lysates were harvested in SUMO buffer containing protease inhibitor cocktail (Roche) and quantified using the DC protein assay kit, also known as the SUMO protein assay, according to the manufacturer’s protocol (Bio-Rad). Equivalent amounts of protein were separated on sodium dodecyl sulfate-10% polyacrylamide gels and transferred to membranes. Membranes were blocked in phosphate-buffered saline (PBS) containing 5% milk and 0.1% Tween 20 solution and incubated with primary antibody. Immunoblotts were probed with the following antibodies: anti-FLAG (Sigma; 1:2,000), anti-R (Argene; 1:250), anti-z (Santa Cruz BZ-1; 1:250), anti-EAD (BMRF1; Vector; 1:250), anti-β-actin (Sigma; 1:5,000), anti-p53 (Santa Cruz; 1:250), anti-LMP1 (Dako; 1:250), anti-p53Ser15 (Cell Signaling Technology; 1:1,000), and anti-ATM (Cell Signaling Technology; 1:1,000).

**Infection and packaging of lentivirus.** Lentivirus vectors expressing short hairpin RNAs (shRNAs) against a control sequence (Sigma catalog no. SHC002 or Addgene plasmid 1864 [82]), ATM (Open Biosystems catalog no. RHS4333-NM_000051), or p53 (Open Biosystems catalog no. RHS4333-NM_000054) were used to produce lentivirus as previously de- scribed according to the Open Biosystems protocol (79). 293T cells were transfected with the lentivirus expression plasmids and the packaging plasmids psPAX2 (Addgene plasmid 12260, a gift of Didier Trono) and VSVG (Addgene plasmid 12259, a gift of Didier Trono) using Lipofectamine 2000 reagent (Invitrogen). Supernatant was collected 3 days posttransfection and filtered through a 0.8-µm filter. The indicated EBV-positive cell lines were then transduced by incubation with filtered medium. After 3 days of incubation, stable cell lines were selected with 1 µg/ml puromycin. AGS-Akata cell lines were continuously passaged in puromycin (1 µg/ml) and G418 (400 µg/ml). Mutu I cells were selected for 18 days in puromycin (1 µg/ml) prior to induction with TGF-β.

**Reverse transcription-PCR (RT-PCR).** RNA was isolated from Mutu I cells treated with or without ATM inhibitor (10 µM) and/or TGF-β (5 µg/ml) 18 h postinduction using a Qiagen RNeasy minikit. RNA was quantitated, DNase treated, and used to make cDNA with the ImProm-II reverse transcription system kit (Promega) according to the manufacturer’s protocol. PCR was then performed using the cDNA as a template to detect Z and beta-2 microglobulin (β2M) transcripts. The following primers were used for PCR: Z-For (5′-CACGGTAGTGTGCAGCATGTT GC-3′), Z-Rev (5′-CCCGAGATCAAGCAGAAGCCG-3′), B2M-For (5′-TTTGGCCTGGAGGGCATCC-3′), and B2M-Rev (5′-ATCTT CAACCTGCAATGATG-3′).

**RESULTS**

**ATM kinase activity is required for activation of efficient EBV early lytic gene expression by various lytic reactivation-inducing stimuli in several different Burkitt lymphoma lines.** To ex- amine if ATM activity mediates the ability of the DNA damage-inducing chemotherapy agent paclitaxel to induce EBV early lytic gene expression, we treated Akata BL cells with or without paclitaxel in the presence or absence of the ATM inhibitor KU55933. KU55933 is an ATP competitor highly specific to the ATM kinase (40). As anticipated, we found that paclitaxel was unable to acti- vate expression of the EBV latent viral proteins, BMRF1 and Z, in the presence of the ATM inhibitor (Fig. 1A). Unexpectedly, however, in the same experiment we found that the ATM inhibitor also prevented lytic reactivation in response to the HDAC inhibitor sodium butyrate. Since the Akata BL line does not express p53 (26), these results suggest that ATM promotes lytic EBV reactivation by both HDACi and paclitaxel in a p53-independent manner.

To determine if ATM activity is required for EBV early lytic gene expression in multiple different cell lines and to determine whether this requirement is dependent upon the type of lytic reactivation-inducing agent used, we treated two additional EBV+ BL lines (Mutu I and Kem I) with different types of lytic reactivation-inducing agents in the presence and absence of the ATM inhibitor. The results of these studies indicated that ATM is also required for efficient lytic reactivation in response to the cytokine TGF-β (Fig. 1B and C) in both Kem I cells and Mutu I cells. Similarly, the amount of lytic protein expression induced following activation of the B cell receptor signaling pathway (using anti- IgG) in Mutu I cells was likewise attenuated in the presence of the ATM inhibitor (Fig. 1C). The ability of the proteasome inhibitor bortezomib to induce lytic protein expression in Mutu I cells was also reduced by ATM inhibition (Fig. 1D).

Finally, we also compared the abilities of the DNA-demethylating agent 5′-azacytidine to induce lytic protein expression, versus the switch between type I and type III latency, in the presence and absence of the ATM inhibitor in Mutu I cells. 5-Azacytidine has been shown to convert BL cells with a restricted form of viral latency (type I) to a less restricted form (type III) (62) and also to induce lytic protein expression (4). Although ATM inhibitor treatment had no effect on the ability of 5-azacytidine to induce expression of the LMPI protein (expressed in type III but not type I latency), it blocked 5-azacytidine-mediated activation of lytic proteins (Fig. 1E). Together, these results demonstrate that activity of the ATM kinase is important for activation of EBV early lytic gene expression in response to a variety of different types of lytic reactivation-inducing stimuli in EBV-positive B cells. Additionally, since each of the BL lines used in the above studies does not express wild-type p53 (26, 41, 96), these results suggest that the ATM effect is independent of wild-type p53 function.

**ATM activity is required for activation of EBV early lytic gene expression by various lytic reactivation-inducing stimuli in epithelial lines.** We next asked if ATM kinase activity is also important for EBV reactivation in epithelial cells. For these studies, an EBV-positive gastric carcinoma line, AGS-Akata, was treated with several different lytic reactivation-inducing stimuli, including sodium butyrate, SAHA (an HDACi), and cisplatin, in the presence or absence of the ATM inhibitor. As shown in Fig. 2A, the ATM inhibitor reduced the amount of lytic Z and BMRF1 protein expression induced by all three agents tested. Since ROS have recently been shown to activate ATM kinase activity (36, 37), we next asked if hydrogen peroxide treatment of AGS-Akata cells reactivates EBV and, if so, whether this effect requires ATM. We found that hydrogen peroxide efficiently induces lytic protein expression in AGS-Akata cells and that this effect is indeed ATM dependent (Fig. 2B). These results suggest that ATM kinase activity is also important for EBV reactivation in EBV-positive epithelial cells.
confirm whether ATM expression is required for efficient viral reactivation in AGS-Akata cells. AGS-Akata cells were infected with two different lentiviruses expressing different shRNAs directed against ATM, or two different control shRNA vectors, and stably infected cell lines were selected with puromycin. The various AGS-Akata lines were then treated with or without hydrogen peroxide, and immunoblot analysis was performed to examine the amount of lytic EBV protein expression. As shown in Fig. 3A, both of the ATM shRNA-expressing lines had decreased ATM expression compared to the lines infected with either of the two control shRNA vectors. Furthermore, neither of the two cell lines knocked down for ATM expression could be induced into the lytic form of viral protein expression by hydrogen peroxide (Fig. 3A). These results confirm that the ATM kinase is essential for efficient EBV lytic reactivation by ROS.

We next used shRNA against ATM to determine if knocking down ATM inhibited TGF-β-induced lytic reactivation in Mutu I BL cells. Mutu I cells were transduced with lentiviruses expressing either two different control or two different ATM-targeting shRNAs. Cells were selected with puromycin for 18 days and induced with or without TGF-β for 2 days. As shown in Fig. 3B, TGF-β did not induce lytic protein expression of BMRF1 or Z as efficiently when ATM expression levels were decreased. These results suggest that ATM is also important for TGF-β-induced EBV early lytic protein expression.

ATM is required for Na- and R-, but not Z-, induced EBV lytic protein expression in AGS-Akata cells. Since we previously showed that lytic EBV reactivation can be induced in AGS-Akata cells following overexpression of the viral Z, R, or Na protein (38), we next examined the effect of the ATM kinase inhibitor on the ability of each of these viral proteins to induce lytic protein expres-
tion. AGS-Akata cells were transfected with control, Na, Z, or R expression vectors in the presence or absence of the ATM inhibitor, and lytic protein expression was examined by Western blot analysis. The ATM inhibitor reduced the amount of endogenous viral BZLF1 and early BMRF1 expression induced by either Na or R transfection (Fig. 4A and B). However, the ATM inhibitor did not affect the ability of transfected Z protein to activate BMRF1 expression (Fig. 4B). These results suggest that ATM activity may be primarily required for activation of the Z promoter, since bypassing the need to activate this promoter by supplying a Z expression vector abrogated the need for ATM.

To determine if ATM kinase activity is important for activation of BZLF1 gene transcription, RNA was isolated from Mutu I cells treated with or without the ATM inhibitor, in the presence or absence of the TGF-β cytokine. RT-PCR was performed on the RNA samples using primers to amplify the BZLF1 transcript or the control beta-2 microglobulin (B2M) cellular gene transcript. As shown in Fig. 4C, BZLF1 transcription was induced in the presence of TGF-β, and the ATM inhibitor blocked this effect. These results further support the hypothesis that ATM activity is important for activation of the BZLF1 promoter.

The EBV-PK is not required for lytic induction by hydrogen peroxide. The EBV protein kinase (EBV-PK; encoded by the BGLF4 gene) has been shown to activate ATM via phosphorylation of Tip60, and it has been suggested that EBV-PK-mediated activation of ATM is important for viral replication (55). Therefore, we determined if EBV-PK is required for hydrogen peroxide-mediated EBV lytic reactivation. AGS cell lines stably infected with wild-type (WT) B95.8 virus, or a previously described EBV-PK mutant virus (66), were generated and shown to have the expected phenotype in regard to expressing the hyperphosphorylated form of the BMRF1 protein (an easily observed EBV-PK-dependent form of BMRF1) (15, 31) (Fig. 5). To determine if EBV-PK is required for induction of Z expression by H2O2, AGS-PKmut cells were treated with or without H2O2 in the presence or absence of the ATM inhibitor (KU55933) and examined by Western blot analysis for Z expression 24 h later (Fig. 5). H2O2 treatment activated Z expression in cells lacking the EBV-encoded protein ki-
nase, and this effect required ATM. Therefore, these results suggest that EBV-PK-mediated activation of ATM is not required for induction of lytic viral reactivation by chemicals such as hydrogen peroxide, which can efficiently activate ATM in EBV-negative cells (37).

p53 is required for hydrogen peroxide-induced EBV lytic reactivation. Since reactive oxygen species are known to activate p53 (14) and we previously demonstrated that wild-type p53 is important for Na- and R-mediated EBV lytic reactivation in AGS-Akata cells (38), we next asked whether the ability of hydrogen peroxide treatment to induce lytic reactivation in this cell type requires p53. AGS-Akata cells were knocked down for ATM or p53 expression using lentiviruses expressing shRNAs against ATM or p53 and then treated with or without hydrogen peroxide. In cells knocked down for either ATM or p53 expression, the lytic reactivation-inducing effect of hydrogen peroxide was highly attenuated (Fig. 6). Furthermore, we found that hydrogen peroxide treatment of AGS-Akata cells (which have wild-type p53) induces p53 phosphorylation at serine 15 and that this phosphorylation was reduced by both the ATM and p53 shRNAs. These results suggest that the ability of hydrogen peroxide to induce lytic viral reactivation in AGS-Akata cells is both ATM and p53 dependent and that ATM is required for efficient p53-Ser15 phosphorylation following hydrogen peroxide treatment of AGS-Akata cells.

ATM is not required for lytic EBV DNA replication when Zp activation is bypassed by transfection of Z protein. Whether ATM is required for EBV lytic DNA replication per se (downstream of early lytic protein activation) is unclear, since two previous papers have yielded conflicting results (50, 55). Therefore, to further investigate the requirement for ATM in EBV DNA replication, we overexpressed the Z protein in 293 cells latently infected with wild-type EBV and then treated with or without the ATM inhibitor. Virus was harvested 3 days posttransfection, and virus titers were determined using a green Raji cell assay. As seen in AGS-Akata cells, we found that ATM is not required for Z-induced lytic protein expression in 293-EBV cells (Fig. 7B). Furthermore, we found that the ATM inhibitor did not inhibit (and in fact somewhat increased) Z-induced virus production (Fig. 7A). Similar results were obtained in a second experiment. These results suggest that ATM is not required for lytic EBV DNA replication per se, at least when the Z protein is overexpressed and the need to activate the Zp in the endogenous viral genome is bypassed.

Nutlin-3 activates EBV lytic protein expression in B cell lines that have wild-type p53 (Kem III and LCLs). Since wild-type p53 activation is important for EBV lytic reactivation in at least a subset of EBV-positive cell lines, we next asked if nutlin-3, a drug which inhibits the interaction between MDM2 and p53 and thus stabilizes p53 expression (92), can reactivate EBV lytic infection in B cell lines that have wild-type p53. The Kem III BL line and an

![FIG 5](image5.png) EBV-PK is not required for early lytic protein expression induced by hydrogen peroxide. (A) AGS-WT and PKmut cells were generated and transfected with the indicated combinations of Z, R, and EBV-PK expression vectors, and Western blot analysis was performed to detect hyper- and hypophosphorylated BMRF1. Antibodies against Z and β-actin were also included as controls. (B) AGS-PKmut cells were treated with or without H2O2 (300 μM) in the presence or absence of the ATM inhibitor KU55933 (10 μM), and Western blot analysis using antibody against BMRF1 or Z was used to detect early lytic protein expression. β-Actin was included as a loading control.

![FIG 6](image6.png) p53 and ATM are required for hydrogen peroxide-induced early lytic protein expression. AGS-Akata cells were knocked down for ATM or p53 expression using shRNA-expressing lentiviruses. Stable cell lines were treated with or without hydrogen peroxide (H2O2, 300 μM), and Western blot analysis was performed to detect BMRF1 or Z lytic protein expression. Western blots were also probed for total p53 and p53 phosphorylated on Ser15. β-Actin was used as a loading control. DMSO, dimethyl sulfoxide.

![FIG 7](image7.png) ATM kinase activity is not required for Z-induced EBV virus production. EBV+ 293 cells were transfected with or without Z and treated with either dimethyl sulfoxide (DMSO) or the ATM inhibitor KU55933 (10 μM). Each condition was performed in triplicate. (A) Three days posttransfection, supernatant was collected and filtered and virus titers were determined using a green Raji unit titration assay. The number of green Raji units per μl of virus was counted and graphed for each condition. (B) Western blot analysis of the transfected EBV+ 293 cell lysates was performed to examine Z, BMRF1, and β-actin expression levels.
Nutlin-3 treatment did not induce lytic reactivation in EBV was enhanced, as expected, by nutlin-3 treatment. In contrast, nutlin-3. Additionally, total p53 and p53-Ser15 phosphorylation cell lines, BMRF1 and Z expression was upregulated in response to protein expression, and p53-Ser15 phosphorylation (Fig. 8). In both early-passage lymphoblastoid cell line (LCL) (LCL donor 4), which both express wild-type p53 (41, 96), were treated with nutlin-3 or vehicle control for 2 days, and Western blot analysis was performed to examine EBV lytic protein expression, total p53 protein expression, and p53-Ser15 phosphorylation (Fig. 8). In both cell lines, BMRF1 and Z expression was upregulated in response to nutlin-3. Additionally, total p53 and p53-Ser15 phosphorylation was enhanced, as expected, by nutlin-3 treatment. In contrast, nutlin-3 treatment did not induce lytic reactivation in EBV+ BL lines (including Kem I and Mutu I) that do not express wild-type p53 (data not shown). Together, these results demonstrate that nutlin-3 can induce EBV lytic reactivation in EBV-infected B cells that express wild-type p53.

Both p53 and ATM kinase activity are required for nutlin-3-induced EBV lytic reactivation. We next examined whether p53 activity is required for the ability of nutlin-3 to induce EBV lytic protein expression. AGS-Akata cells stably infected with control or p53 shRNA lentiviruses were treated with or without nutlin-3 and examined for BMRF1, Z, and p53-pSer15 expression by Western blot analysis (Fig. 8C). Nutlin-3 treatment efficiently induced lytic viral protein expression in AGS-Akata cells, and this effect required p53. These results confirm that p53 is required for the ability of nutlin-3 to induce EBV lytic reactivation. Of note, nutlin-3 was also recently shown to upregulate lytic gene transcrip-

FIG 8 Nutlin-3 induces EBV lytic protein expression in a p53- and ATM-dependent manner. (A and B) Kem III (A) or LCL donor 4 (B) cells were treated with dimethyl sulfoxide (DMSO) or nutlin-3 (10 μM) for 2 days, and cells were harvested for Western blot analysis. Antibodies against BMRF1 and Z were used to examine EBV lytic protein expression, and antibodies against total p53 or p53-phospho-Ser15 were used to confirm activation of p53. β-Ac-
tin was used as a loading control. (C) AGS-Akata cells transduced with lentivirus expressing either control or shRNA against p53 were treated with DMSO or nutlin-3 (10 μM) for 2 days, and Western blot analysis was performed on cell lysates using antibodies against BMRF1, Z, p53-phospho-Ser15, and β-
-actin. (D) LCL donor 4 cells were pretreated with DMSO or the ATM inhibitor KU55933 for 1 h and induced with or without nutlin-3 for 48 h. Western blot analysis was performed to examine BMRF1, p53-phospho-Ser15, and β-actin expression.

DISCUSSION

We previously demonstrated that treatment of EBV-positive tumor cells with DNA-damaging agents such as chemotherapy or irradiation can induce lytic reactivation (28, 95), and we and others have recently shown that p53 is required for lytic reactivation by HDACi (13, 38). Since ATM is induced by DNA damage and plays an important role in activating p53 function, in this paper we have explored the role of ATM in the ability of chemotherapy, versus other lytic reactivation-inducing agents (with multiple different proposed mechanisms of action), to reactivate EBV. Using an ATM-specific inhibitor (KU55933), as well as an ATM knockdown approach, we found that ATM activity is important for EBV early lytic gene expression in both EBV-positive B cells and EBV-positive epithelial cells regardless of the lytic reactivation-inducing agent used. These studies reveal an unexpected and critical role of ATM activation in mediating the latent-to-lytic EBV switch.

In EBV-positive Burkitt lines, we found that ATM activity is required for lytic EBV gene expression induced by agents with multiple different proposed mechanisms of action, including HDACi, chemotherapy, TGF-β, B cell receptor engagement with anti-IgG, the proteosome inhibitor bortezomib, and the demethylating agent 5-azacytidine (Fig. 1). Additionally, our results show that ATM kinase activity is important for reactivation in the EBV-positive epithelial cell line AGS-Akata when cells are induced with HDACi (sodium butyrate or SAHA), the chemotherapy reagent cisplatin, or hydrogen peroxide (Fig. 2). It is important to note that most of these lytic induction agents have been reported to induce ATM activation, including HDACi, chemotherap-
ATM at Ser-1981, hydrogen peroxide was recently shown to induce activation of ATM via a conformational alteration in the protein that does not result in Ser-1981 phosphorylation (37). Furthermore, oxidative stress has been shown to activate ATM without necessarily leading to activation of DNA damage-responsive genes (36). Recent studies demonstrated that hydrogen peroxide induces reactivation of another gammaherpesvirus, Kaposi’s sarcoma-associated herpesvirus (KSHV) (36, 98). Additionally, hydrogen peroxide has been shown to induce Z transcription (52). Here we demonstrate that induction of lytic EBV infection by inducing oxidative stress with hydrogen peroxide requires ATM kinase activation (Fig. 2). It remains unclear if EBV lytic proteins, including Z, R, or Na, are able to induce ROS. However, the KSHV R homologue (KSHV RTA) has been shown to activate ROS, and this effect is important for RTA-mediated viral reactivation (36, 98). Therefore, in the future it will be interesting to determine if one or more of the EBV lytic proteins likewise induces ROS and promotes EBV lytic infection at least partially through this mechanism.

Additionally, we found that ATM activity is required for lytic reactivation induced by overexpression of the EBV Na or R protein, but not Z, suggesting that ATM is required for the ability of Na, R, and presumably certain cellular transcription factors to activate the Z promoter in the context of the endogenous viral genome (Fig. 4A and B). Furthermore, we demonstrated that ATM activity is required for Z transcription in EBV+ cells induced with TGF-β, further suggesting that ATM is required for activation of the Z promoter (Fig. 4C). We also found that the EBV-encoded protein kinase, EBV-PK, which has been shown to activate ATM through phosphorylation and activation of Tip60 (55), is not required for lytic reactivation induced by hydrogen peroxide (Fig. 5). Thus, activation of the Z promoter by this agent is independent of EBV-PK activation of ATM.

Our group and others have shown that p53 is important for EBV lytic reactivation in many cell lines (15, 17, 38), and p53 has been reported to form a complex with SP1 that binds to, and activates, the Z promoter (17). In addition, p53 was recently shown to inhibit expression of the ZEB-1 and ZEB-2 proteins (49), which are potent repressors of the Z promoter (24), by inducing expression of microRNAs that degrade ZEB-1/-2. Furthermore, similar to our findings with ATM, we previously showed that Na and R, but not Z, require p53 to induce lytic gene expression (38).

Thus, we initially hypothesized that the major role of ATM during lytic EBV reactivation might be to enhance p53 transcriptional function. Although our data here confirm that p53 plays an important role during early stages of EBV lytic reactivation in cells that contain wild-type p53, we find that ATM must also promote EBV reactivation via p53-independent mechanisms, since ATM inhibition also blocked EBV reactivation in p53-negative and p53 mutant cells. Thus, additional cellular ATM substrates must also function to regulate viral gene expression. Since ATM phosphorylates over 700 cellular proteins (64), we are unable to examine the role of each known ATM substrate on viral reactivation. In addition to p53, we have examined the effect of the cellular KAP1 protein on lytic EBV gene expression, since the unphosphorylated form of KAP1 promotes heterochromatin and KSHV viral latency (12, 83), whereas the ATM-phosphorylated form (Ser824) relaxes heterochromatin (11). We did not find that either phosphomimetic p53 or KAP1 mutants could compensate for the effect of ATM knockdown on EBV reactivation (data not shown). Thus, we speculate that multiple different ATM targets are important for EBV reactivation. One such ATM target may be the histone variant H2AX, since the ATM-phosphorylated form of H2AX (which is phosphorylated at the same residue by the murid herpesvirus 68 [MHV68] viral kinase) has been reported to promote viral reactivation of the MHV68 gammaherpesvirus in certain cell types (11, 90).

Interestingly, inhibition of ATM enhances the ability of EBV to transform primary B cells in vitro (72), and at least three different EBV latency proteins (EBNA1, EBNA3C, and LMP1) inhibit the DNA damage response (10, 72). LMP1 decreases expression of both ATM and p53 (35, 44). Furthermore, both LMP1 and LMP2A inhibit p53-mediated apoptosis (7, 30, 75). LMP1 and LMP2A have both been reported to inhibit lytic viral reactivation in vitro (3, 67, 68, 74), and we recently reported that LMP1- and LMP2A-expressing B cells do not express early lytic viral proteins in EBV-infected humanized mice, even when mice are infected with a “superlytic” EBV mutant that results in high-level Z/BMRF1 expression (59). Our results here suggest that LMP1 and/or LMP2A might inhibit lytic EBV reactivation at least partially through inhibition of ATM and/or p53 function.

Previous studies examining if ATM is required for EBV DNA replication downstream of early lytic protein activation have yielded conflicting results. Here, we demonstrate that ATM is not required for lytic EBV DNA replication when Zp activation is bypassed by transfection of the Z protein (Fig. 7). Interestingly, the group that found ATM to be dispensable for lytic viral replication induced replication by transfecting cells with Z (50), while the group that found ATM to be required for viral DNA replication induced replication by treating cells with anti-IgG and did not examine the effect of the inhibitor on early lytic protein expression (55). Therefore, our data suggest that ATM is important for EBV lytic infection primarily at the level of Zp activation and not for viral DNA replication per se.

Based on these results and the work of others, we propose a model in which ATM contributes to the initial steps of EBV lytic reactivation (Fig. 9). In this model, cellular stresses, including DNA damage or production of ROS, lead to ATM activation. ATM activation then leads to phosphorylation of ATM target substrates that activate the EBV Zp through effects on viral chromatin structure (for example, H2AX phosphorylation) and/or by increasing p53 transcriptional function. Expression of Z then leads to activation of R expression, and together Z and R induce expression of all the lytic EBV proteins, including the EBV-encoded protein kinase (EBV-PK). Since the EBV protein kinase (encoded by the BGLF4 gene) has been shown to enhance ATM activity through phosphorylation of Tip60 (54, 55), this leads to further amplification of ATM kinase activity. Viral DNA replication, which occurs downstream of Z and R activation, may also further activate ATM, although ATM activity is not required for viral DNA replication.

Finally, our results here suggest that drugs which activate ATM and/or p53 might be useful for “lytic induction therapy.” Lytic induction therapy, in which the lytic form of EBV infection is purposely activated in latently infected tumor cells, has been proposed as a novel way to promote EBV-dependent killing of tumor cells. We demonstrate that nutlin-3, a drug which stabilizes p53 expression by antagonizing its interaction with the E3 ligase MDM2, is able to induce lytic reactivation in an
ATM- and p53-dependent manner in EBV-infected cells expressing wild-type p53.

ACKNOWLEDGMENTS

We thank Janet Mertz for reviewing the manuscript.

This work was supported by grants T32 AI078985, R01-CA58853, R01-CA66519, and P01-CA022443 from the National Institutes of Health.

REFERENCES

34. Gruffat H, Manet E, Rigole A, Sergeant A. 1990. The enhancer factor

FIG 9 Hypothesized model by which ATM contributes to lytic EBV reactivation. Cellular stresses such as DNA damage and reactive oxygen species (ROS) induce ATM activation. ATM then activates the EBV immediate-early promoter, Zp, through effects on viral chromatin structure (for example, by enhancing KAP1 and/or H2AX phosphorylation) and/or by increasing p53 transcriptional function. Induction of Zp activity leads to expression of the IE protein, which results in R expression. Z and R induce transcription of the early lytic viral proteins, including the EBV-encoded protein kinase (PK), which then further activates ATM activity through phosphorylation of Tip60. Viral DNA replication, which occurs downstream of Z and R activation, may further activate ATM (data not shown).


